$5.95
0.34% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US92829J1043
Symbol
DWTX

Virios Therapeutics Inc Stock price

$5.95
-0.24 3.88% 1M
+0.49 8.87% 6M
+3.46 138.96% YTD
+3.52 144.86% 1Y
-1.90 24.16% 3Y
-244.05 97.62% 5Y
-244.05 97.62% 10Y
-244.05 97.62% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-0.02 0.34%
ISIN
US92829J1043
Symbol
DWTX
Industry

Key metrics

Basic
Market capitalization
$13.7m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
68.2%
Return on Equity
-20.0%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-31.7m | $-17.5m
Net Income
$-40.0m | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-390.1% | -42.9%
Net Income
-530.6% | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-20.8
FCF per Share
-
Short interest
4.4%
Employees
-
Rev per Employee
-
Show more

Is Virios Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Virios Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Virios Therapeutics Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Virios Therapeutics Inc forecast:

Buy
88%
Hold
13%

Financial data from Virios Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.86 9.86
115% 115%
-
- Research and Development Expense 22 22
879% 879%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -32 -32
390% 390%
-
Net Profit -40 -40
531% 531%
-

In millions USD.

Don't miss a Thing! We will send you all news about Virios Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Virios Therapeutics Inc Stock News

Neutral
Accesswire
9 days ago
- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled ...
Neutral
GlobeNewsWire
14 days ago
- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release -
Neutral
Accesswire
21 days ago
ATLANTA, GA / ACCESS Newswire / October 30, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development‐stage biotechnology company developing new medicines to treat pain and neuropathy, announced today that it will report third quarter 2025 financial results on Thursday, November 6, 2025, before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeuti...
More Virios Therapeutics Inc News

Company Profile

Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.

Head office United States
CEO Gregory Duncan
Founded 2012
Website dwtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today